Abu Dhabi Stem Cells Centre And Burjeel Medical City Collaborate To Enhance Bone Marrow Transplant Services

Abu Dhabi Stem Cells Centre (ADSCC) and Burjeel Holdings PLC have formed a strategic alliance to enhance bone marrow transplant and cellular therapy services at Burjeel Medical City (BMC). This collaboration aims to improve access to advanced treatments for both adult and pediatric patients dealing with blood cancer, genetic disorders, autoimmune diseases, and more. The partnership will contribute to creating a comprehensive ecosystem for advanced research and cellular therapy, reinforcing Abu Dhabi's reputation as a global healthcare hub.

The agreement between ADSCC and BMC focuses on increasing patient accessibility in the UAE and surrounding regions. By combining their expertise, both institutions aim to align with Abu Dhabi's mission of becoming a global leader in medical excellence and innovation. Patients currently receiving care at BMC and ADSCC, as well as new patients, will benefit from this collaboration.

John Sunil, CEO of Burjeel Holdings, expressed the vision behind this partnership: "Our vision is to create a comprehensive, world-class bone marrow transplant programme that delivers the highest standards of care while also pushing the boundaries of innovation. This partnership is a major step forward in achieving that goal. Together, we are setting new benchmarks in patient outcomes and medical excellence."

ADSCC is leading the way in providing advanced treatments for orthopedic, neurological, rheumatological, autoimmune, and burn-related conditions using stem cells and cellular therapies. These innovative services will be integrated into BMC's various specialties to enhance patient care further. The focus on regenerative medicine services is a key aspect of this partnership.

Prof. Yendry Ventura, CEO of ADSCC and Adjunct Professor at UAE University, highlighted ADSCC's pioneering role: "Guided by the UAE's visionary leadership, ADSCC was the first to introduce bone marrow transplantation and cellular therapy in the UAE in 2020, providing advanced critical care regionally and running high-level research and clinical trials in the field. As demand grew, ADSCC expanded to offer CAR-T Cell Therapy, offering further cutting-edge treatment options to patients."

Strengthening Healthcare Infrastructure

This collaboration also aims to leverage BMC’s robust infrastructure alongside ADSCC’s advanced research capabilities. Dr. Fatima Alkaabi from ADSCC emphasized its significance: "This collaboration marks a transformative moment for expanding bone marrow transplant in UAE. By extending the advanced research and clinical capabilities of ADSCC with BMC’s robust infrastructure and expertise, we are not only enhancing the standards of care for our patients but also reinforcing Abu Dhabi’s position as a life sciences hub."

Prof. Humaid Al Shamsi from Burjeel Cancer Institute stated: "This partnership represents a crucial advancement in our ability to provide comprehensive and cutting-edge care to patients with complex hematological conditions. By combining the expertise of both institutions, we are creating a seamless continuum of care and driving forward the research and clinical practices that will shape the future of regenerative medicine and hematology in the region."

The strategic partnership between ADSCC and Burjeel Holdings PLC signifies an important step towards advancing healthcare services in Abu Dhabi. By integrating their strengths in research, infrastructure, and innovative treatments, they aim to set new standards for patient care while solidifying Abu Dhabi's status as a leading healthcare destination globally.

With inputs from WAM